Effect of Efavirenz on High-Density Lipoprotein Antioxidant Properties in HIV-Infected Patients

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * In previous work, we showed a long-term and concentration-dependent beneficial effect of the non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) on high-density lipoproteins (HDL) in human immunodeficiency virus (HIV)-infected patients. * Furthermore, it has been suggested that instead of the current practice of only measuring HDL-chelesterol values, the evaluation of HDL function, namely its antioxidant properties, might be an improved tool for identifying subjects at increased risk for cardiovascular events. * Paraoxonase-1 (PON-1) is an enzyme associated with HDL that is responsible for HDL antioxidant function. WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity. AIMS: A long-term and concentration-dependent beneficial effect of efavirenz (EFV) on cholesterol associated with high-density lipoprotein (HDL-c) in human immunodeficiency virus (HIV)-infected patients has been documented. Furthermore, it has been suggested that, instead of the current practice of only measuring HDL-c values, the evaluation of HDL quality might be an improved tool for identifying subjects at increased risk of cardiovascular events. Paraoxonase-1 (PON-1) is an enzyme associated with HDL that is involved in the onset of cardiovascular disease and responsible for HDL antioxidant function. The aim of the present study was to investigate the effect of EFV on the circulating activity of PON-1 in HIV-infected patients. METHODS: The patients included were adults with a documented HIV-1 infection, nontreated or treated with antiretroviral regimens including EFV 600 mg once daily as first therapeutic regimen for at least 3 months. The influence of treatment with EFV, HDL-c and CD4 cell count on PON-1 activity was analysed. RESULTS: HIV-infected White patients treated with EFV had higher PON-1 activity [77.35 U l(-1) (65.66, 89.04)] (P < 0.05) and higher PON-1 activity : HDL-c ratio [1.88 (1.49, 2.28)] (P < 0.01) than untreated patients. PON-1 activity was higher in Black patients (P < 0.001) and in patients with a CD4 cell count >500 cells ml(-1) (P= 0.0120). CONCLUSIONS: EFV-based antiretroviral regimens are associated with HDL particles with a better antioxidant function, i.e. with a higher PON-1 activity. The PON-1 activity of Black patients is higher than that found in Whites regardless of treatment. Ethnicity should be taken into consideration when studying drug effects on PON-1 activity.

Caracterização da aterosclerose sub-clínica e doença coronária em doentes com síndrome metabólica e diabetes mellitus

RESUMO- Introdução: A obesidade e a Síndrome Metabólica (SM) são atualmente um importante problema de saúde pública, com prevalências crescentes, que se acompanham também por aumento da prevalência de Diabetes Mellitus (DM).Estudos prévios demonstram associação destas entidades com o aumento de risco de eventos cardiovasculares, em particular a DM. A SM tem sido uma entidade muito debatida nos últimos anos, com aparecimento de diversas definições, contribuindo para resultados díspares no que diz respeito à influência da SM nas doenças cardiovasculares. Também têm sido descritas variações étnicas e regionais. Para além de alguns estudos epidemiológicos na população geral, a informação relativamente à sua influência na presença de doença cardiovascular é desconhecida em Portugal, em particular em populações com suspeita de doença coronária. Objetivos - Esclarecimento de questões relacionadas com a prevalência de SM e a sua influência na evolução de doença ateroclerótica arterial por avaliação de uma população com suspeita de doença coronária. População e Métodos - Estudo observacional, transversal, com inclusão prospetiva de indivíduos admitidos letivamente para realização de angiografia coronária por suspeita de doença coronária, tendo sido também efetuadas análises laboratoriais e ecografia carotidea para avaliação da espessura intima-média carotidea (EIMc) e da presença de placas carotídeas. Efetuou-se avaliação dos parâmetros demográficos, antropométricos, determinação do perfil lipídico, glicémia e insulinémia. Os exames angiográficos foram analisados por análise quantitativa semi-automática. Foram excluídos indivíduos com antecedentes conhecidos de doença cardíaca. Resultados - Incluíram-se 300 doentes, com idade média de 64 ± 9 anos, 59% do género masculino. A prevalência de SM de acordo com a definição da AHA/NHLBI foi 48,4% (ajustada para idade e género da população portuguesa) e a prevalência de DM foi 14,8% (ajustada). A concordância global das três definições mais recentes de SM foi de apenas 43%. A prevalência de SM aumenta com a idade e é também mais elevada no género feminino. O componente mais frequente foi a hipertensão arterial, seguido pela obesidade abdominal, a elevação da glicémia e por fim as alterações dos triglicéridos e do colesterol HDL. Por outro lado, a presença de doença coronária significativa (lesões ≥50%) ocorreu em apenas 51,3% dos doentes, sendo ainda mais baixa no género feminino. Demonstrou-se também uma baixa capacidade preditiva para doença coronária dos testes não invasivos clássicos, em particular no género feminino. A prevalência de doença coronária significativa foi idêntica nos indivíduos com SM comparativamente com indivíduos sem alterações metabólicas (46,3% vs. 48,2%, respectivamente), sendo mais elevado nos diabéticos (65,2%). Os fatores predizentes independentes de doença coronária significativa foram a idade, o género masculino, a elevação da glicémia e dos triglicéridos. Pelo contrário, o Índice de Massa Corporal (IMC) mostrou uma associação protetora relativamente à presença de doença coronária. A SM não é fator predizente de doença coronária. Relativamente às dimensões dos vasos coronários, o IMC correlaciona-se positivamente e a glicémia / DM correlacionam-se negativamente. A EIMc aumenta com o aumento da idade e no género masculino. A EIMc foi intermédia nos doentes com SM (0,88 ± 0,31 mm) comparativamente com os doentes diabéticos (0,97 ± 0,34 mm) e os indivíduos “Normais” (0,85 ± 0,34 mm). Os fatores predizentes independentes de EIMc foram a idade, o género masculino, o colesterol HDL e a insulinémia. A EIMc permite predizer com uma acuidade moderada a presença de doença coronária significativa (AUC 0,638), em particular no género feminino, sendo um fator predizente independente de presença de doença coronária (OR 2,35, IC 95% 1,04-5,33. p=0,04). Apesar de não se correlacionar com o número de vasos coronários com doença, correlacionou-se com a gravidade da doença (pelo score de Gensini). A insulinémia e o índice HOMA aumentam diretamente com a idade e com o IMC, sendo contudo sobreponíveis em ambos os géneros. Os fatores predizentes de índice HOMA (resistência à insulina) foram o IMC, bem como os restantes componentes de SM, estando o índice HOMA relacionado com a presença de SM e o número dos seus componentes presentes. O limiar para resistência à insulina foi de 2,66 e para SM foi 2,41. Ao contrário das restantes definições de SM, a definição da AHA/NHLBI não é predizente da presença de DM no género masculino. A associação da resistência à insulina com doença coronária foi limiar (OR 1,13, IC 95% 1,00-1,28, p=0,045). Conclusões - Numa população com suspeita de doença coronária, a prevalência de SM é muito elevada (superior a 50%), sendo a prevalência de DM de 23%. Também a obesidade e o excesso de peso foram extremamente prevalentes nesta população. A concordância entre definições de SM é baixa. A hipertensão arterial e a obesidade abdominal são os componentes mais frequentes de SM, sendo menos prevalentes as alterações lipídicas. Pelo contrário, a presença de doença coronária significativa foi muito baixa, em particular nas mulheres. A SM não se associou à presença de doença coronária significativa, estando esta mais dependente das alterações do metabolismo glicídico e dos triglicéridos, bem como de outros fatores de risco não modificáveis, nomeadamente a idade e o género. A EIMc da carótida comum e a presença de placas carotídeas é mais elevada nos indivíduos diabéticos, estando também ligeiramente aumentada nos doentes com SM, sendo os fatores predizentes de EIMc apenas a idade, o género, a hiperinsulinémia bem como os níveis baixos de colesterol HDL. A utilização da avaliação da EIMc na estratificação de risco pré-angiografia coronária, poderá ser útil no género feminino. A hiperinsulinémia e o índice HOMA (índice de resistência à insulina), estão relacionados com o IMC e consequentemente com a presença de obesidade, embora também se correlacione de forma independente com os outros componentes de SM. A resistência à insulina associou-se à presença de SM. Relativamente à capacidade preditiva da coexistência com DM, verificou-se associação com a definição da NCEP-ATP III e da IDF, contudo, a definição da AHA/NHLBI só foi predizente de DMnas mulheres. -------------ABSTRACT - Introduction: Obesity and Metabolic Syndrome (MS) are a major public health problem, with increasing prevalence, that follows the increase in diabetes prevalence. Previous studies showed an association of both entities with increased cardiovascular risk, particularly diabetes. MS has been debated in the last few years, with several definitions and different results when analysed the influence of MS on cardiovascular diseases. There are also some regional and ethnical variations. Beyond general population epidemiological studies, information about the influence on cardiovascular disease in Portugal is unknown, particularly in patients with suspected coronary disease. Objectives- To clarify several questions regarding the prevalence of MS and the influence in arterial atherosclerotic disease by evaluation of a population with suspected coronary artery disease. Population and Methods- Observational, cross-sectional study with prospective inclusion of individuals admitted electively for coronary angiography with suspicion of coronary artery disease. All individuals also performed laboratorial evaluation and carotid ultrasound to evaluate carotid intima-media thickness (cIMT) and carotid plaques. We also evaluated demographic, anthropometric parameters, lipid profile, blood glucose and blood insulin. Angiographic data was obtained by semi-automated quantitation. Individuals with previously known cardiac history were excluded from the study. Results- We included 300 individuals with a mean age of 64 ± 9 years, 59% males. MS prevalence according to AHA/NHLBI definition was 48.4% (adjusted for age and gender of the Portuguese population) and the adjusted prevalence of diabetes was 14.8%. Global agreement between the more recent three definitions of MS was only 43%. MS prevalence increases with age and is also higher in women. The most frequent components were hypertension and abdominal obesity, followed by elevated glucose and triglicerides and low HDL-cholesterol. Significant coronary artery disease (stenosis ≥50%) was present in only 51.3% of patients, being lower in females. Non-invasive tests also had a low predictive capacity, particularly in females. The prevalence of significant coronary disease was identical in patients with MS compared with normal metabolism individuals (46.3% vs. 48.2%, respectively), being higher in diabetics (65.2%). Independent predictive factors for coronary disease were age, male gender, high blood glucose and triglycerides. On the contrary, Body Mass Index (BMI) was a protective factor for coronary disease. MS wasn’t a predictor of coronary disease. BMI showed a positive correlation with coronary vessel diameter and glucose /diabetes had a negative correlation. CIMT increased with age and was higher in males. CIMT was intermediate in patients with MS (0.88 ± 0.31 mm) when compared to diabetic patients (0.97 ± 0.34 mm) and “Normal” individuals (0.85 ± 0.34 mm). Independent predictors for cIMT were age, male gender, HDL-cholesterol and insulin. CIMT had a moderate predictive accuracy for coronary disease (AUC 0,638), particularly in females and is an independent predictor of the presence of significant coronary disease (OR 2.35, 95% CI 1.04-5.33. p=0.04). Although it did not correlate with the number of diseased coronary arteries, it correlated with coronary disease severity by the Gensini score. Insulin and HOMA index increase directly with age and BMI, but were identical in both genders. Predictive factors for HOMA index (insulin resistance) were BMI as well as the other MS components. HOMA index is related to MS and the number of its components. The cut-off for insulin resistance was 2.66 and for MS 2.41. Unlike other MS definitions, AHA/NHLBI definition is not a predictor of diabetes in males. There was a borderline association between insulin resistance and coronary disease (OR 1.13, 95% CI 1.00-1.28, p=0.045). Conclusions - In a population of patients with suspected coronary disease, MS prevalence is extremely high (above 50%) with a diabetes prevalence of 23%. Also obesity and overweight are very prevalent in this population. Global agreement between MS definitions is however low. Hypertension and abdominal obesity are the most frequent components, with a lower prevalence of lipid abnormalities. Coronary disease prevalence was low, particularly in women. MS wasn’t associated with coronary disease. Coronary disease was related to glucose and triglycerides, as well as with other non-modifiable factors such as age and gender. CIMT and carotid plaques are increased in diabetic patients, and also slightly elevated in patients with MS, but cIMT independent predictors were age, male gender, insulin and HDLcholesterol. CIMT can be useful in risk stratification before coronary angiography particularly in women. Elevated insulin and HOMA index (an insulin resistance index) are related with BMI and consequently with obesity, and it was also correlated with other MS components. Insulin resistance was associated with MS. The presence of diabetes was associated with the presence of MS by NCEP-ATP III and IDF definitions; however, AHA/NHLBI definition was only predictive of diabetes in females.

Relação entre o consumo de medicamentos do aparelho cardiovascular e os internamentos

RESUMO - Objetivos: Caracterizar a evolução do consumo de medicamentos da área cardiovascular entre 2002 e 2011. Caracterizar a evolução dos internamentos com diagnóstico principal cardiovascular, da taxa de mortalidade intra-hospitalar e da idade média dos doentes no episódio de internamento. Estabelecer relação entre o consumo de medicamentos e os episódios de internamento. Metodologia: Por consulta à base de dados do Infarmed, determinar a evolução do consumo de medicamentos por distrito de Portugal continental, medido em embalagens consumidas/1000 habitantes. Por consulta à base de dados de GDH, determinar a evolução do nº de internamentos por doença cardiovascular dos residentes em cada distrito, determinado em internamentos/1000 habitantes. Determinar a evolução da taxa de mortalidade dos episódios, avaliada em mortes/ 100 episódios. Determinar a evolução da idade média. Correlação estatística entre o consumo e nº internamentos, mortalidade e idade. Regressão linear simples entre o consumo e nº internamentos, mortalidade e idade. Resultados: O consumo de cardiotónicos e antiarrítmicos diminuiu, -26,45% e -16,48%, respetivamente. O consumo de anti hipertensores, vasodilatadores e antidislipidémicos aumentou, respetivamente, 78,73%; 11,18% e 180,91%. A incidência de EAM aumentou 0,03%, a de IC 0,97% e a de AVC diminuiu -21,42%. A mortalidade diminuiu para EAM, IC e AVC, respetivamente, -31,48%; -18,03% e -15,06%. A idade média de ocorrência de EAM manteve-se, a de IC aumentou 2,2 anos e a de AVC aumentou 1,5 anos. 23,9% da variação da incidência de AVC pode ser explicada pelo consumo. A variação da taxa de mortalidade por EAM, IC e AVC que pode ser explicada pelo consumo é de 30,9%; 13,0% e 32,9%. O consumo explica 48,3% e 73,5%, da variação da idade média de ocorrência de internamentos por IC e AVC, respetivamente. Os anti hipertensores e os antidislipidémicos são as subclasses com correlação estatisticamente significativa mais relevante com a diminuição da taxa de mortalidade e aumento da idade média. Conclusão: O consumo explica sensivelmente 50% do aumento da idade média, e em menor percentagem a evolução do nº de internamentos e da taxa de mortalidade. As subclasses dos anti hipertensores e dos antidislipidémicos são as principais responsáveis pelo aumento do consumo, mas também são as que tem correlação estatisticamente significativa mais forte com os ganhos em saúde.

Molecular targeting of proteins by homocysteine: implications in familial and clinical hypercholesterolemia

Cardiovascular diseases (CVDs) are one of the leading causes of death and disability worldwide and one of its underlying causes is hypercholesterolemia. Hypercholesterolemia can have genetic (familial hypercholesterolemia, FH) and non-genetic causes (clinical hypercholesterolemia, CH), the first much more severe, with occurrence of premature atherosclerosis. While the pathophysiological role of homocysteine (Hcy) on CVD is still controversial, molecular targeting of protein by S and N-homocysteinylation offers a new paradigm to be considered in the vascular pathogenesis of hypercholesterolemia. On this regard, the present study aims to give new insights on protein targeting by Hcy in both CH and FH conditions. A total of 187 subjects were included: 65 normolipidemic and 122 hypercholesterolemic. Total (tHcy) and free (fHcy) fractions were quantified in serum samples after validation of an HPLCFD method, to assess S-homocysteinylation. Also, the lactonase (LACase) activity of paraoxonase-1 (PON1) was quantified by a colorimetric assay, as a surrogate of N-homocysteinylation. tHcy does not differ among groups. Nevertheless, fHcy declines in the hypercholesterolemic groups, with more evidence to the FH population. Consequently, there seems to be an increase of Shomocysteinylation, regardless of lipid lowering therapy (LLT). Also, despite of LLT use, LACase activity is lower in FH, thus the risk for protein N-homocysteinylation seems to be higher. Moreover, the decrease in LACase/ApoA1 and LACase/HDL ratios in FH, shows that HDL is dysfunctional in this population, despite its normal concentration values. Data supports that the pathophysiological role of Hcy on hypercholesterolemia may reside in its ability to post-translationally modify proteins. This role is particularly evident in FH condition. In the future, it will be interesting to identify which target proteins are modified and thus involved in vascular pathology progression.

Contributo para o estudo dos efeitos da passagem à situação (e idade) de reforma na frequência das principais doenças crónicas em Portugal

RESUMO - Introdução: A transição para a reforma é um acontecimento que pode acarretar alterações suscetíveis de afetar o estado de saúde. Vários estudos têm investigado os efeitos da reforma no estado de saúde, embora poucos o tenham investigado, especificamente, nas doenças crónicas. As recentes políticas de aumento da idade de reforma, assim como a ausência de consenso sobre os efeitos da reforma na saúde, atribuem-lhe ainda maior importância. Constituem objetivos do presente estudo quantificar a associação entre a Passagem à situação de reforma (e idade de reforma) e a frequência de cada uma das principais doenças crónicas, no sentido dos efeitos da reforma nestes indicadores de saúde (doença respiratória crónica, diabetes, doença cardiovascular, AVC, depressão e cancro). Material e Métodos: Desenvolveu-se um estudo transversal, no qual foram analisados os dados provenientes das amostras representativas da população portuguesa SHARE 2011 e ECOS 2013. As associações foram quantificadas através do cálculo do Odds ratio por Regressão Logística Binária com avaliação do confundimento e modificação de efeito. As variáveis de doença crónica foram medidas por auto-reporte. Foram considerados os reformados que se encontrassem em processo de reforma (ou seja, reformados há 5 anos ou menos) e que não se tivessem reformado por doença. Resultados: A reforma não se encontrou significativamente associada a nenhuma das doenças crónicas consideradas, excetuando-se: i) o cancro (na amostra ECOS), para o qual foi fator protetor; ii) e a doença cardiovascular (na amostra SHARE), para a qual teve um efeito prejudicial, mas apenas em não hipertensos. A reforma em idade antecipada pareceu encontrar-se associada a um pior estado de saúde, relativamente à reforma em idade legal (ou após). Tal observou-se no Cancro (nas amostras ECOS e SHARE), na Diabetes (na amostra SHARE), e no AVC em pessoas sem Doença Cardiovascular (na amostra SHARE). Pelo contrário, em pessoas com Doença Cardiovascular a reforma antecipada pareceu constituir um fator protetor. Discussão e conclusões: As diferenças observadas nos resultados entre amostras poderão, entre outros, atribuir-se às diferentes populações em estudo, dimensões amostrais e desenhos de amostragem. Os resultados obtidos não são muito diferentes dos que têm sido descritos na bibliografia, ainda que haja um número reduzido de estudos sobre esta matéria. Indicam que, eventualmente, as recentes alterações de aumento da idade de reforma poderão expandir o grupo de pessoas que se reformam antecipadamente, podendo resultar, eventualmente, num aumento da prevalência de doenças crónicas na população portuguesa. Os mecanismos através dos quais a reforma poderá influenciar a ocorrência de doenças crónicas permanecem por explicar, embora os seus principais fatores de risco pareçam representar importantes modificadores de efeito.

Custos indirectos associados à obesidade em Portugal

RESUMO - A obesidade constitui um importante problema de saúde pública com consequências económicas de grande dimensão. Os obesos têm um risco acrescido de contrair doenças e de sofrer morte prematura devido a problemas como a diabetes, hipertensão arterial, AVC, insuficiência cardíaca e algumas neoplasias malignas. O presente estudo tem como objectivo estimar o custo económico indirecto (valor da produção perdida) associado à obesidade em Portugal no ano de 2002. O estudo adopta uma abordagem tipo custos da doença baseada na prevalência. Os dados são retirados do Inquérito Nacional de Saúde e estatísticas de rotina publicadas pelo INE e por outros organismos oficiais. Consideram-se como obesas pessoas com índice de massa corporal (IMC) ≥ 30 kg/m2 e estabelecem-se como limites etários para participação em actividades económicas produtivas as idades compreendidas entre os 15 e os 64 anos. A estratégia de imputação de custos ao factor de risco obesidade caracteriza- se por estimar, para a população portuguesa, as proporções de doença e morte prematura atribuíveis à obesidade e em multiplicar as estimativas populacionais encontradas pelo valor da produtividade económica potencial das pessoas afectadas. O custo indirecto total da obesidade em Portugal no ano de 2002 foi estimado em 199,8 milhões de euros. A mortalidade contribuiu com 58,4% deste valor (117 milhões de euros) e a morbilidade com 41,6% (83 milhões de euros). Os custos da morbilidade advêm de mais de 1,6 milhões de dias de incapacidade anuais, principalmente por faltas ao trabalho associadas a doenças do sistema circulatório e diabetes tipo II. Os custos da mortalidade são o resultado de 18 733 potenciais anos de vida activa perdidos, numa razão de 3 mortes masculinas por cada morte feminina. Os resultados indicam que a obesidade acarreta consideráveis perdas económicas para o país. Comparando os resultados com um estudo complementar que calculou os custos directos (em cuidados de saúde) da obesidade, verifica-se que a componente indirecta representa 40,2% do total dos custos da obesidade. A implementação de estratégias que prevenissem ou reduzissem a incidência e prevalência de obesidade em Portugal poderia gerar ganhos de produtividade elevados. Para conhecer a dimensão destes ganhos é necessária mais investigação sobre os benefícios clínicos e relação custo-efectividade de estratégias para a redução da obesidade.

Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length

Compelling biological and epidemiological evidences point to a key role of genetic variants of the TERT and TERC genes in cancer development. We analyzed the genetic variability of these two gene regions using samples of 2,267 multiple myeloma (MM) cases and 2,796 healthy controls. We found that a TERT variant, rs2242652, is associated with reduced MM susceptibility (OR?=?0.81; 95% CI: 0.72-0.92; p?=?0.001). In addition we measured the leukocyte telomere length (LTL) in a subgroup of 140 cases who were chemotherapy-free at the time of blood donation and 468 controls, and found that MM patients had longer telomeres compared to controls (OR?=?1.19; 95% CI: 0.63-2.24; ptrend ?=?0.01 comparing the quartile with the longest LTL versus the shortest LTL). Our data suggest the hypothesis of decreased disease risk by genetic variants that reduce the efficiency of the telomerase complex. This reduced efficiency leads to shorter telomere ends, which in turn may also be a marker of decreased MM risk.

Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium

Type 2 diabetes (T2D) has been suggested to be a risk factor for multiple myeloma (MM), but the relationship between the two traits is still not well understood. The aims of this study were to evaluate whether 58 genome-wide-association-studies (GWAS)-identified common variants for T2D influence the risk of developing MM and to determine whether predictive models built with these variants might help to predict the disease risk. We conducted a case–control study including 1420 MM patients and 1858 controls ascertained through the International Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32–2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76–0.85). Interestingly, a prediction model including those T2D-related variants associated with the risk of MM showed a significantly improved discriminatory ability to predict the disease when compared to a model without genetic information (area under the curve (AUC)=0.645 vs AUC=0.629; P=4.05×10-06). A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348 and NOTCH2rs10923931 variants (Pinteraction=0.001 and 0.0004, respectively). Men carrying the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a significantly decreased risk of MM whereas an opposite but not significant effect was observed in women (ORM=0.71 and ORM=0.66 vs ORW=1.22 and ORW=1.15, respectively). These results suggest that TD2-related variants may influence the risk of developing MM and their genotyping might help to improve MM risk prediction models.

Coronary arterial disease after electroconvulsive therapy: a case report

Objectives Unipolar depression (UPD) is a leading cause of global burden of diseases, particularly among the elderly, whose treatment may be challenging. In such cases, ECT is often recommended due to its safety and efficacy. This report presents a case of a 67-year-old male inpatient that developed a rare cardiac complication during ECT. Methods Clinical case report with patient’s consent and bibliographic review. Results A 67-year-old male inpatient with recurrent severe psychotic depression was hospitalized and ECT was indicated after failure of the pharmacological treatment. A comprehensive clinical pre-evaluation revealed only nonspecific ST-segment changes in electrocardiogram. During the 7th ECT session, it was observed transitory ST-segment depression followed by a discrete increase of plasma troponin I. Severe tri-vessel coronary artery stenosis was found and a percutaneous coronary angioplasty was performed, with satisfactory psychiatric and cardiac outcomes. Conclusions Unipolar depression (UPD) and cardiovascular disease are often coexistent conditions, especially among the elderly. In the current case, myocardial ischemia was detected lately during ECT therapy and its treatment allowed the UPD treatment to be completed adequately.

An epidemiological study determining blood pressure in a Portuguese cohort: the Guimaraes/Vizela study

Surveying the evolution of blood pressure (BP) levels and hypertension (HTN) prevalence is important. A stringent strategy was utilized in a population cohort study. The BP was measured at two visits at least 3 months apart, and the results were analyzed using the following two methods: the Surveillance method (three BP measurements were performed in one visit, and the results were compared with those published previously for the identical method) and the Clinical method (three measurements per visit for two visits, and the concordant results in both visits were used to determine the BP classification). A total of 2542 subjects completed the evaluation. Using the Clinical method, an average systolic/diastolic BP value of 129.8/76.8?mm?Hg was obtained, and the prevalence of HTN was 31.6%. Of the hypertensive patients, 74.3% were aware of his/her condition; 69.1% were treated and 40.8% of those treated had adequate BP control. A total of 24.7% of subjects changed his/her BP classification between visits, and 13.7% misreported HTN. Using the Surveillance method, we determined that the average global SBP has been maintained, with HTN prevalence increasing in this region, drifting from reported trends nationally and worldwide. There has been improvement in the proportion of treated and controlled subjects; however, the Surveillance method overestimated the HTN prevalence and underestimated the proportion of treated and controlled subjects. The BP levels were higher than observed worldwide in high-cardiovascular (CV) risk countries as well as higher than the minimum risk exposure level for developing CV disease.

Alcohol and atherosclerosis

Observational studies have attributed a protective effect to alcohol consumption on the development of atherosclerosis and cardiovascular morbidity and mortality. Alcohol intake in the amount of one to two drinks per day results in an estimated 20-40% reduction in cardiovascular events. An additional protective effect, according to major cohort studies, has been attributed to wine, probably due to antioxidant effects and platelet antiaggregation agents. On the other hand, the influence of different patterns of alcohol consumption and environmental factors may explain a great part of the additional effect of wine. Protection may be mediated by modulation of other risk factors, because alcohol increases HDL-C, produces a biphasic response on blood pressure, and modulates the endothelial function, while it neither increases body weight nor impairs glucose-insulin homeostasis. Alcohol may also have a direct effect on atherogenesis. Despite these favorable effects, the current evidence is not enough to justify prescribing alcohol to prevent cardiovascular disease.

Some predictors of cardiovascular mortality among the elderly population of Botucatu (SP)

OBJECTIVE: To detect factors associated with cardiovascular mortality in the elderly of Botucatu. METHODS: We evaluated 29 variables of interest in a cohort of patients aged ³60 using data from a survey conducted between 1983/84. The elderly cohort was analyzed in 1992 to detect the occurrence of cardiovascular deaths. Survival analysis was performed using the Kaplan-Meier method, the log-rank test, and Cox regression analysis. Three models were adapted for each group of variables, and a final model was chosen from those variables selected from each group. RESULTS: We identified predictor for cardiovascular death according to age for elderly males not supporting the family, not possessing a vehicle, and previous cardiovascular disease. In elderly females, the predictor variables were previous cardiovascular disease and diabetes mellitus. CONCLUSION: Socioeconomic indicators (family heading and vehicle ownerrship) may be added to well stabilished medical factors (diabete mellitus and hypertension to select target groups for programs intended to reduce deaths due to cardiovascular diseases in elderly people.

Williams-Beuren syndrome: cardiovascular abnormalities in 20 patients diagnosed with fluorescence in situ hybridization

OBJECTIVE: To evaluate the cardiovascular findings and clinical follow-up of patients with Williams-Beuren syndrome. METHODS: We studied 20 patients (11 males, mean age at diagnosis: 5.9 years old), assessed for cardiovascular abnormalities with electrocardiography and Doppler echocardiography. Fluorescence in situ hybridization (FISH) was used to confirm the diagnosis of the syndrome. RESULTS: Elastin gene locus microdeletion was detected in 17 patients (85%) (positive FISH), and in 3 patients deletion was not detected (negative FISH). Sixteen patients with a positive FISH (94%) had congenital cardiovascular disease (mean age at diagnosis: 2,3 years old). We observed isolated (2/16) supravalvular aortic stenosis and supravalvular aortic stenosis associated (11/16) with pulmonary artery stenosis (4/11); mitral valve prolapse (3/11); bicuspid aortic valve (3/11); aortic coarctation (2/11), thickened pulmonary valve (2/11); pulmonary valvular stenosis (1/11); supravalvular pulmonary stenosis (1/11); valvular aortic stenosis (1/11); fixed subaortic stenosis (1/11); pulmonary artery stenosis (2/16) associated with pulmonary valvar stenosis (1/2) and with mitral valve prolapse (1/2); and isolated mitral valve prolapse (1/16). Four patients with severe supravalvular aortic stenosis underwent surgery (mean age: 5.7 years old), and 2 patients had normal pressure gradients (mean follow-up: 8.4 years). CONCLUSION: A detailed cardiac evaluation must be performed in all patients with Williams-Beuren syndrome due to the high frequency of cardiovascular abnormalities.

Evaluation of Sexual Dimorphism in the Efficacy and Safety of Simvastatin/Atorvastatin Therapy in a Southern Brazilian Cohort

Background: Dyslipidemia is the primary risk factor for cardiovascular disease, and statins have been effective in controlling lipid levels. Sex differences in the pharmacokinetics and pharmacodynamics of statins contribute to interindividual variations in drug efficacy and toxicity. Objective: To evaluate the presence of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin treatment. Methods: Lipid levels of 495 patients (331 women and 164 men) were measured at baseline and after 6 ± 3 months of simvastatin/atorvastatin treatment to assess the efficacy and safety profiles of both drugs. Results: Women had higher baseline levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared with men (p < 0.0001). After treatment, women exhibited a greater decrease in plasma TC and LDL-C levels compared with men. After adjustment for covariates, baseline levels of TC and LDL-C influenced more than 30% of the efficacy of lipid-lowering therapy (p < 0.001), regardless of sex. Myalgia [with or without changes in creatine phosphokinase (CPK) levels] occurred more frequently in women (25.9%; p = 0.002), whereas an increase in CPK and/or abnormal liver function was more frequent in in men (17.9%; p = 0.017). Conclusions: Our results show that baseline TC and LDL-C levels are the main predictors of simvastatin/atorvastatin therapy efficacy, regardless of sex. In addition, they suggest the presence of sexual dimorphism in the safety of simvastatin/atorvastatin. The effect of sex differences on receptors, transporter proteins, and gene expression pathways needs to be better evaluated and characterized to confirm these observations.

Lipoprotein (a): Structure, Pathophysiology and Clinical Implications

The chemical structure of lipoprotein (a) is similar to that of LDL, from which it differs due to the presence of apolipoprotein (a) bound to apo B100 via one disulfide bridge. Lipoprotein (a) is synthesized in the liver and its plasma concentration, which can be determined by use of monoclonal antibody-based methods, ranges from < 1 mg to > 1,000 mg/dL. Lipoprotein (a) levels over 20-30 mg/dL are associated with a two-fold risk of developing coronary artery disease. Usually, black subjects have higher lipoprotein (a) levels that, differently from Caucasians and Orientals, are not related to coronary artery disease. However, the risk of black subjects must be considered. Sex and age have little influence on lipoprotein (a) levels. Lipoprotein (a) homology with plasminogen might lead to interference with the fibrinolytic cascade, accounting for an atherogenic mechanism of that lipoprotein. Nevertheless, direct deposition of lipoprotein (a) on arterial wall is also a possible mechanism, lipoprotein (a) being more prone to oxidation than LDL. Most prospective studies have confirmed lipoprotein (a) as a predisposing factor to atherosclerosis. Statin treatment does not lower lipoprotein (a) levels, differently from niacin and ezetimibe, which tend to reduce lipoprotein (a), although confirmation of ezetimibe effects is pending. The reduction in lipoprotein (a) concentrations has not been demonstrated to reduce the risk for coronary artery disease. Whenever higher lipoprotein (a) concentrations are found, and in the absence of more effective and well-tolerated drugs, a more strict and vigorous control of the other coronary artery disease risk factors should be sought.